Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen

MLA

Sherry Pierce, et al. “Relation between the Duration of Remission and Hyperglycemia during Induction Chemotherapy for Acute Lymphocytic Leukemia with a Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone/Methotrexate–cytarabine Regimen.” Cancer, vol. 100, Mar. 2004, pp. 1179–85. EBSCOhost, https://doi.org/10.1002/cncr.20071.

APA

Sherry Pierce, Hagop Kantarjian, Maria E. Cabanillas, Deborah A. Thomas, Carmen P. Escalante, Susan O’Brien, Marina Konopleva, & Mary Ann Weiser. (2004). Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen. Cancer, 100, 1179–1185. https://doi.org/10.1002/cncr.20071

Chicago

Sherry Pierce, Hagop Kantarjian, Maria E. Cabanillas, Deborah A. Thomas, Carmen P. Escalante, Susan O’Brien, Marina Konopleva, and Mary Ann Weiser. 2004. “Relation between the Duration of Remission and Hyperglycemia during Induction Chemotherapy for Acute Lymphocytic Leukemia with a Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone/Methotrexate–cytarabine Regimen.” Cancer 100 (March): 1179–85. doi:10.1002/cncr.20071.